A robot-based gait training therapy for pediatric population with Cerebral Palsy using the CPWalker robotic platform

Conditions

Cerebral palsy Nervous System Diseases Cerebral palsy

Cristina Bayón, Óscar Ramírez, Eduardo Rocón, Teresa Marín-Lorenzo, Beatriz Moral-Saiz et al. (8 authors)

2020-08-04

10.17979/spudc.9788497497749.0244

A robot-based gait training therapy for pediatric population with cerebral palsy: goal setting, proposal and preliminary clinical implementation

Cristina Bayón, Teresa Martín Lorenzo, Beatriz Moral-Saiz, Óscar Ramírez, Álvaro Pérez-Somarriba et al. (8 authors)

Journal of NeuroEngineering and Rehabilitation2018-07-2667 citations

10.1186/s12984-018-0412-9

Interventions

Four children with CP are recruited to train with a robotic platform (CPWalker) two non-consecutive days per week for eight weeks (16 total sessions). The sessions consist of a 10-15 minutes warm-up a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Children aged 11 to 18 years suffering from spastic diplegia 2. Gross Motor Function Classification System (GMFCS) levels I to IV 3. Maximum weight 75 kg 4. Anthropometric measures of lower limbs according to the exoskeleton of CPWalker 5. Capable of understanding the proposed exercises 6. Able to signal pain or discomfort

Exclusion criteria

Exclusion criteria: 1. Patients who experimented concomitant treatments 3-months prior study (e.g. orthopedic surgery or botulinum toxin) 2. Children with muscle-skeletal deformities or unhealed skin lesions in the lower limbs that could prevent the use of the exoskeleton 3. Patients with critical alterations of motor control as dystonia, choreoathetosis or ataxia 4. Aggressive or self-harming behaviors 5. Severe cognitive impairment

Design outcomes

Primary

Measure	Time frame
Gait function is measured using 3D gait analysis at baseline, 8 and 16 weeks	—

Secondary

Measure	Time frame
1. Gait-speed is measured using 10-meter walking test at baseline, 8 and 16 weeks 2. Global responses involved and endurance is measured using 6-minutes walking test at baseline, 8 and 16 weeks 3. Maximum isometric strength is measured using a hand-held dynamometer 4. Selective voluntary motor control is measured using the Selective Control Assessment of Lower Extremity (SCALE) at baseline, 8 and 16 weeks 5. The changes in gross motor function are measured using the Gross Motor Function Measure (GMFM-88) dimensions D (standing) and E (walking) at baseline, 8 and 16 weeks 6. Psychological influence of fear and pain is measured using a personal kinesiophobia assessment at baseline, 8 and 16 weeks 7. Users' satisfaction is measured using the Gillette Functional Assessment Questionnaire (FAQ) at baseline, 8 and 16 weeks	—

Measure

Time frame

1. Gait-speed is measured using 10-meter walking test at baseline, 8 and 16 weeks 2. Global responses involved and endurance is measured using 6-minutes walking test at baseline, 8 and 16 weeks 3. Maximum isometric strength is measured using a hand-held dynamometer 4. Selective voluntary motor control is measured using the Selective Control Assessment of Lower Extremity (SCALE) at baseline, 8 and 16 weeks 5. The changes in gross motor function are measured using the Gross Motor Function Measure (GMFM-88) dimensions D (standing) and E (walking) at baseline, 8 and 16 weeks 6. Psychological influence of fear and pain is measured using a personal kinesiophobia assessment at baseline, 8 and 16 weeks 7. Users' satisfaction is measured using the Gillette Functional Assessment Questionnaire (FAQ) at baseline, 8 and 16 weeks

—

Countries

Spain

Outcome results

None listed